愛知県がんセンターは、愛知県が運営する日本初のがん専門病院である。同県名古屋市千種区鹿子殿に所在する。

During the past decade, Aichi Cancer Center Hospital conducted 39 clinical trials. In the 10-year time frame, 39 clinical trials started and 25 clinical trials were completed, i.e. on average, 64.1% percent of trials that started reached the finish line to date. In the past 5 years, 17 clinical trials started and 19 clinical trials were completed. i.e. 111.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Aichi Cancer Center Hospital" #1 sponsor was "Pfizer" with 13 trials, followed by "Takeda" with 5 trials sponsored, "Eli Lilly and Company" with 4 trials sponsored, "Kyowa Kirin Co., Ltd." with 4 trials sponsored and "Daiichi Sankyo Co., Ltd." with 4 trials sponsored. Other sponsors include 18 different institutions and companies that sponsored additional 22 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Aichi Cancer Center Hospital" #1 collaborator was "AstraZeneca" with 4 trials as a collaborator, "Eli Lilly and Company" with 3 trials as a collaborator, "Daiichi Sankyo, Inc." with 2 trials as a collaborator, "Loxo Oncology, Inc." with 2 trials as a collaborator and "Alpha-A, Inc." with 1 trials as a collaborator. Other collaborators include 11 different institutions and companies that were collaborators in the rest 21 trials.

According to Clinical.Site data, the most researched conditions in "Aichi Cancer Center Hospital" are "Breast Cancer" (5 trials), "Breast Neoplasms" (5 trials), "Colorectal Cancer" (3 trials), "Advanced Hepatocellular Carcinoma" (2 trials) and "Carcinoma, Non-Small-Cell Lung" (2 trials). Many other conditions were trialed in "Aichi Cancer Center Hospital" in a lesser frequency.

Most popular intervention types in "Aichi Cancer Center Hospital" are "Drug" (49 trials), "Biological" (3 trials), "Other" (3 trials), "Device" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (14 trials), "Rituximab" (4 trials), "Abemaciclib" (3 trials), "Bendamustine" (3 trials) and "Fulvestrant" (3 trials). Other intervention names were less common.

The vast majority of trials in "Aichi Cancer Center Hospital" are 42 trials for "All" genders and 9 trials for "Female" genders.

Currently, there are NaN active trials in "Aichi Cancer Center Hospital". undefined are not yet recruiting, 9 are recruiting, 14 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 25 completed trials in Aichi Cancer Center Hospital, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Aichi Cancer Center Hospital, 10 "Phase 1" clinical trials were conducted, 17 "Phase 2" clinical trials and 23 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".